Search clinical trials for: SEP-363856

Total 320 results

Sumitomo Pharma America, Inc.

Completed

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Schizophrenia

United States, Serbia, Colombia, Bulgaria, Russian Federation, Ukraine
Sumitomo Pharma Co., Ltd.

Terminated

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Schizophrenia

Japan, Taiwan, China, Philippines
Sumitomo Pharma America, Inc.

Completed

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Schizophrenia

United States, Serbia, Croatia, Bulgaria, Latvia, Russian Federation, Ukraine
Sunovion

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (SEP-363856)

Schizophrenia

United States
Sunovion

Completed

A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia

Schizophrenia

Hungary, United States, Romania, Ukraine, Russian Federation
Sumitomo Pharma Co., Ltd.

Terminated

A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

Schizophrenia

Japan
Sumitomo Pharma America, Inc.

Terminated

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

Schizophrenia

United States, Serbia, Ukraine, Croatia, Colombia, Russian Federation, Bulgaria, Latvia
Sumitomo Pharma Co., Ltd.

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

Schizophrenia

Japan
Sunovion

Completed

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

Schizophrenia

United States, Ukraine, Russian Federation, Hungary, Romania
Sumitomo Pharma America, Inc.

Completed

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

Schizophrenia

United States
Sunovion

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

Parkinson Disease Psychosis

United States
Sumitomo Pharma Co., Ltd.

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

Schizophrenia

Japan
Sunovion

Completed

A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Recruiting

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States, Spain, Japan, Bulgaria, Estonia, Finland, Slovakia, Sweden
Otsuka Pharmaceutical Development & Commercialization...
Sumitomo Pharma Co., Ltd.; Sumitomo Pharma America, Inc.

Recruiting

A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Sumitomo Pharma America, Inc.

Completed

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Enrolling by invitation

An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Completed

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

Schizophrenia

United States
Sunovion

Completed

A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging

Schizophrenia

United Kingdom
Sunovion

Completed

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

Schizophrenia

United States
Klinikum St. Georg gGmbH

Completed

Trigeminus-evoked Somatosensory Potentials in Patients Undergoing Carotid Surgery (TRISEP)

Carotid Surgery

Germany
Sunovion

Completed

Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics

Schizophrenia

United Kingdom
Sunovion

Completed

A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression

Depressive Episode | Bipolar 1 Depression

Japan, Serbia, United States, Poland, Russian Federation, Bulgaria, Slovakia, Ukraine
University of Arizona
Arizona Biomedical Research Commission (ABRC)

Unknown

Sleep Promotion in Critically Ill and Injured Patients Cared for in the Intensive Care Unit

Sleep Deprivation

United States
i-SEP

Completed

Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery (i-TRANSEP)

Hemorrhage | Blood Loss | Surgical Blood Loss

France
Sumitomo Pharma America, Inc.

Terminated

A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Depressive Episodes, Bipolar I Depression

United States, Bulgaria, Japan, Romania, Canada, Slovakia
Sumitomo Pharma America, Inc.

Completed

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Completed

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

Schizophrenia

United States
Sumitomo Pharma America, Inc.

Terminated

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

Depressive Episodes, Bipolar I Depression

United States, Bulgaria, Japan
Polish Mother Memorial Hospital Research Institute

Completed

The Impact of Positioning on Bottle-feeding in Preterm Infants. A Comparative Study PMMHHRI-2018/V/9-SZB

Bottle Feeding | Premature

Poland
King's College London

Completed

Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study (INTEGRATE)

Schizophrenia | Cannabis Use

United Kingdom
Sunovion

Completed

Adult Attention Deficit Hyperactivity Disorder

Adult Attention Deficit Hyperactivity Disorder

United States
Sunovion

Completed

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

Attention-Deficit Hyperactivity Disorder (ADHD)

United States
Sunovion

Completed

This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.

Narcolepsy

United States
Sunovion

Completed

A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects

Healthy

United States
Réseau Sep Idf Ouest

Completed

Behavior Cognitive Therapy on Fatigue Impact in MS Patients

Fatigue | Relapsing Remitting Multiple Sclerosis | Cognitive Therapy

France
Sunovion

Completed

Dasotraline Pediatric ADHD Study

Attention Deficit Hyperactivity Disorder

United States
Hull University Teaching Hospitals NHS Trust
University of Hull

Completed

Trial of Nonsurgical Treatment of Intermittent Claudication Due to Femoro-popliteal Disease

Intermittent Claudication | Femoropopliteal Disease

United Kingdom
Fundació Institut Germans Trias i Pujol
Fundació La Marató de TV3

Completed

PROMISE (Somatosensory Evoked POtEntials MonItoring During Acute Ischemic StrokE) Study (PROMISE)

Acute Cerebrovascular Accident | Endovascular Procedures

Spain
Uijeongbu St. Mary Hospital
The Catholic University of Korea

Completed

Prognostic Value of P30 After Cardiac Arrest

Out-Of-Hospital Cardiac Arrest

Korea, Republic of
Hasselt University
Charles University, Czech Republic; Queen's University; Haukeland University... and other collaborators

Completed

Psychometric Properties Upper Limb Function Measures Multiple Sclerosis (MCS-III-UL)

Multiple Sclerosis

Belgium
Hasselt University
Charles University, Czech Republic; Queen's University; Haukeland University... and other collaborators

Completed

Psychometric Properties Mobility Measures MS (MCS-III-MOB)

Multiple Sclerosis

Belgium
Sunovion

Completed

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

Attention-Deficit Hyperactivity Disorder (ADHD)

United States
GeNeuro Innovation SAS

Completed

Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease (LOMBARD)

Multiple Sclerosis (MS) | Clinically Isolated Syndrome (CIS) | Secondary Progressive MS | Primary Progressive MS | Relapsing-Remitting MS

France, Spain, Switzerland
Riphah International University

Recruiting

Effects of Speed Endurance Training on Agility and Functional Performance in Soccer Players

Sports Physical Therapy

Pakistan
Bayer

Completed

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

Relapsing Remitting MS (RRMS) | Secondary Progressive MS (SPMS)

France, Germany, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Czech Republic, Italy, Jordan, Lebanon, Turkey, Israel, Portugal, Netherlands, Iran, Islamic Republic of
The Leeds Teaching Hospitals NHS Trust

Unknown

Preventing Job Loss Using Acceptance and Commitment Therapy in Vocational Rehabilitation (MS-Proactive)

Multiple Sclerosis

United Kingdom
University of Aarhus

Completed

Capillary Dysfunction and CD46-immunoreceptor (CD46) Type in MS

Multiple Sclerosis

Denmark
University of Alberta
Alberta Innovates Health Solutions

Completed

Reducing Sedentary Behaviour: A Novel Opportunity for Managing Comorbidity in MS?

Multiple Sclerosis

Canada
Babes-Bolyai University

Completed

Effectiveness of the Social-Emotional Prevention Program Enhanced Version (SEP+)

Child Behavior Problem

Romania

3

Subscribe